<DOC>
	<DOCNO>NCT01524900</DOCNO>
	<brief_summary>This Post Marketing Surveillance study perform open-label , prospective , non-interventional , uncontrolled study Human immunodeficit Virus-1 ( HIV-1 ) infect patient . Data document patient pharmacotherapy nevirapine extend release initiate . Both anti-retroviral therapy ( ART ) na√Øve patient pre-treated patient switch nevirapine immediate release anti-retroviral therapy ( ART ) include study . The decision initiate treatment nevirapine extend release independent study base entirely individual patient need judgement treat physician . The aim study assess safety efficacy treatment adherence nevirapine extend release HIV-1 infect patient routine clinical practice . It plan document five visit patient twenty four week observational period .</brief_summary>
	<brief_title>Observational Study Nevirapine Extended Release Human Immunodeficiency Virus ( HIV ) Patients Daily Clinical Practice</brief_title>
	<detailed_description>Study Design : non-interventional uncontrolled observational study</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Inclusion criterion : 1 . HIV1 infect male female 18 year ; 2. antiretroviral therapy ( ART ) naive pretreated patient switch nevirapine immediate release ART . Exclusion criterion : Consistent current VIRAMUNE prolong release SPC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>